- Sales improved KRW 2.1 billion and Profits improved KRW 4.1 billion compared to last quarter
Samsung BioLogics Co., Ltd. (CEO: Tae Han Kim) today announced its financial results for the first quarter in 2017. The company posted quarterly sales of KRW 107.6 billion and quarterly operating profits of KRW 3.4 billion.
Sales of Samsung Biologics increased KRW 2.1 billion (1.9%) as its product shipments increased. Also as sales increased and SG&A (Selling, General and Administrative Expenses) decreased, operating profits increased KRW 4.1 billion to turn profitable.
It also posted net loss of KRW 33.1 billion, reflecting the equity method of biosimilar development and clinical expenses for the company’s subsidiary, including Samsung Bioepis and Archigen Biotech.
※ Samsung Biologics Financial Result 1Q 2017 (Billion Won)
| 1Q 2017 | 4Q 2016 | QoQ |
Sales | 107.6 | 105.5 | +2.1(1.9%) |
Operating Profit | 3.4 | -0.7 | +4.1(Profitable) |
Net Profit | -33.1 | -57 | +23.9(41.9%) |
- Sales improved KRW 2.1 billion and Profits improved KRW 4.1 billion compared to last quarter
Samsung BioLogics Co., Ltd. (CEO: Tae Han Kim) today announced its financial results for the first quarter in 2017. The company posted quarterly sales of KRW 107.6 billion and quarterly operating profits of KRW 3.4 billion.
Sales of Samsung Biologics increased KRW 2.1 billion (1.9%) as its product shipments increased. Also as sales increased and SG&A (Selling, General and Administrative Expenses) decreased, operating profits increased KRW 4.1 billion to turn profitable.
It also posted net loss of KRW 33.1 billion, reflecting the equity method of biosimilar development and clinical expenses for the company’s subsidiary, including Samsung Bioepis and Archigen Biotech.
※ Samsung Biologics Financial Result 1Q 2017 (Billion Won)
| 1Q 2017 | 4Q 2016 | QoQ |
Sales | 107.6 | 105.5 | +2.1(1.9%) |
Operating Profit | 3.4 | -0.7 | +4.1(Profitable) |
Net Profit | -33.1 | -57 | +23.9(41.9%) |
Share article
Related Content